Gary Hooper

gary-hooper

Gary Hooper joined Velocity as a Venture Partner in January, 2012 when he made an investment into Velocity II Jadoo, L.P. Fund. In his role at Velocity, Gary works to develop an organized and systematic approach for helping startup companies to commercialize their invention or technology. This includes the full spectrum from drafting business and project plans, developing presentation skills, and matching potential investors with startup companies of interest.

Outside of Velocity, Gary is an experienced biotechnology executive with a combination of large company and startup experience. He has been involved in the biotechnology industry since its inception, having joined Genentech in early 1980. While there he served in several management positions, including Senior Director, Business Development. In 1988, he joined Cygnus, Inc. as Vice President of Business Development & Marketing. At Cygnus, a drug delivery company, Gary established five major strategic alliances and was instrumental in establishing the company’s IPO. After Cygnus, he was President & Chief Executive Officer of Pharmetrix, where he streamlined the company, brought it back to profitability, established corporate partnerships and sold the company; he was President and Chief Operating Officer of Pharma Patch and President and Chief Executive Officer of Ciblex Corporation, a developer of therapeutics by inhibiting cell to cell communication. After the acquisition of Ciblex, Gary was Vice President of Business Development at Genencor International, where he was responsible for corporate alliances, contract revenues, licensing agreements and a $35 million Silicon Biotechnology® strategic alliance with Dow Corning. After Genencor, Gary was President & CEO of VerdiChrys Technology, a company pioneering the convergence of biotechnology and industrial chemicals to develop a process for producing inexpensive ethanol.

Gary is a past member of the Board of Directors of Accera, Inc. (a biopharmaceutical company specializing in Alzheimer’s disease) and Chairman of the Human Resources Committee. He is on the Board of Trustees for Sutter Health Sacramento Sierra Region, one of the leading California hospital chains with revenues over $12 billion. He is Chairman of Millennium Group Holdings, and past board member of Joint Venture: Silicon Valley Networks where he developed the Next Silicon Valley Initiative: Convergence of Biotech, Nanotech and Information Technology and served as Chairman of the Technology Convergence Consortium. He is a member of the Licensing Executives Society and past member of the Executive Healthcare Committee and Board of Trustees. Gary is a past member of the Board of Councilors of the College of Letters and Arts and Sciences at the University of Southern California and past member the Scientific Advisory Council of the Technology Commercialization Program at the University of Utah. He is also a Commercial Reviewer for the National Science Foundation.